首页|贝那普利联合阿托伐他汀对慢性心力衰竭患者的疗效及对血浆NT-proBNP的影响

贝那普利联合阿托伐他汀对慢性心力衰竭患者的疗效及对血浆NT-proBNP的影响

扫码查看
目的 研究贝那普利联合阿托伐他汀治疗慢性心力衰竭临床疗效及对血浆N末端脑钠肽原(N-terminal pro-brain natriuretic peptide,NT-proBNP)水平的影响.方法 选取90例慢性心力衰竭患者,按照随机数表法分为观察组和对照组,每组各45例,对照组患者采用贝那普利治疗,观察组采用贝那普利联合阿托伐他汀治疗,6个月后观察2组患者治疗前后心功能左心室舒张末径(left ventricular end-diastolic dimension,LVEDD)、左心室收缩末期内径(left ventricular end systolic dimension,LVESD)、左室射血分数(left ventricular eject fraction,LVEF),炎症因子C反应蛋白(C-reactionprotein,CRP)、白介素-6(interleukin-6,IL-6)、肿瘤坏死因子α(tumor necrosis factorα,TNF-α),血浆NT-proBNP水平变化及治疗疗效.结果 治疗后,观察组LVEDD、LVESD小于对照组,LVEF高于对照组(P<0.05).治疗后,观察组血清CRP、IL-6、TNF-α均低于对照组(P<0.05).观察组血浆NT-proBNP明显低于对照组(P<0.05).观察组总有效率优于对照组95.55%(43/45)vs.77.77%(35/45)(P<0.05).结论 贝那普利联合阿托伐他汀治疗慢性心力衰竭疗效显著,能够降低血浆NT-proBNP水平,改善炎症因子.
Curative efficacy of benazepril combined with atorvastatin on plasma NT-proBNP and its efficacy in chronic cardiac failure
Objective To study curative efficacy of benazepril combined with atorvastatin on N-terminal pro-brain natriuretic peptide (NT-proBNP) and its efficacy in the treatment of chronic cardiac failure. Methods 90 patients of chronic heart failure were selected as research objects. The control group were treated with benazepril, while the observation group were treated with benazepril combined with atorvastatin, 45 cases in each group. Then before and after treatment of 6 months, the cardiac function of left ventricular end-diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left ventricular eject fraction (LVEF), C-reactionprotein (CRP), interleukin- 6 (IL-6, tumor necrosis factor α (TNF-α) and plasma NT-proBNP levels were compared between two groups, and the efficacy was observed. Results After treatment, LVEDD and LVESD in observation group were lower than those in control group, the LVEF was higher than that in control group(P<0.05). The CRP,IL-6 and TNF-αlevels in observation group were lower than those in control group(P<0.05). The plasma NT-proBNP level in observation group was significantly lower than that in control group(P<0.05). The total effective rate of observation group was statistically higher than that that in the control group 95.55%(43/45)vs. 77.77%(35/45)(P<0.05). Conclusion Benazepril combined with atorvastatin in the treatment of chronic heart failure is significant, can reduce plasma NT-proBNP levels, improve the inflammatory factor.

benazeprilatorvastatincombinationchronic cardiac failureN-terminal pro-brain natriuretic peptide

何明、王丽慧、刘金涛

展开 >

嘉兴市中医医院 心血管病科,浙江 嘉兴 314000

贝那普利 阿托伐他汀 联合 慢性心力衰竭 N末端脑钠肽原

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(1)
  • 26
  • 9